Ultragenyx Pharmaceutical | RARE - Los Gastos De Explotación

Precio De Mercado
23.30
Cambio Diario
-0.61 -2.55%
Mensual
4.91%
Anual
-31.75%
Q2 Expectativa
22.66




Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Immunic USD 25.73M 2.91M 2024-09
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Kyowa Hakko Kirin JPY 109.02B 16.08B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Moderna USD 1.54B 259M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xoma USD 22.84M 1.67M 2024-09